Literature DB >> 17253070

[Validation of the Spanish version of the "Bladder control Self-Assessment Questionnarie" (B-SAQ). A new screening instrument for lower urinary tract dysfunction].

M Espuña Pons1, M Puig Clota, P Rebollo Alvarez.   

Abstract

BACKGROUND: Taking into account the high prevalence in our country of Overactive Bladder Syndrome (OAB) ("urgency", with or without incontinence, sometimes associated to an increase in frequency and/or nocturia) and the difficulty to identify it, it would be interesting to have a short patient self assessment screening questionnarie for the evaluation of lower urinary tract symptoms. The objective of the study is to evaluate the psychometric properties of the Spanish version of the Bladder control Self-Assessment Questionnaire (B-SAQ). PATIENTS AND METHODS: 133 women consulting due to lower urinary tract symptoms in a health care centre specialised on uroginecology. The subjects filled the B-SAQ (scales "symptoms" and "discomfort") and the ICIQ-UI SF, and underwent the usual protocol: uroginecologic history, pelvic examination and urodynamic study. Feasibility, validity, and reliability of the B-SAQ were assessed, as well as the ROC curve for the scores of both BCSEQ scales regarding the urodynamic diagnosis of Detrusor Overactivity (DO).
RESULTS: Feasibility: Average administration time, 3.5 (1.5) minutes: 2 women did not answer any of the questionnaires. VALIDITY: the scores for "symptoms" and "discomfort" were higher in those women with a DO diagnosis: "symptoms" = 7.8 (2.6) vs 6.2 (2.3) (p=0.0002); "discomfort" = 9.1 (3) vs 7.8 (3.6) (p=0.03); the Spearman's correlation coefficient between "discomfort" scale and item 3 of the ICIQ-UI SF (affection) was 0.65 (p<0.001). Feasibility: Cronbach's alpha for "symptoms" was 0.722 and 0,889 for "discomfort". According to the COR curve for both scales, a score greater than or equal to 6 showed adequate sensibility and specificity for the DO diagnosis.
CONCLUSIONS: The B-SAQ is an easy-use instrument which shows adequate feasibility, validity and reliability for its use in clinical practice as screening instrument for OAB.

Entities:  

Mesh:

Year:  2006        PMID: 17253070     DOI: 10.1016/s0210-4806(06)73578-1

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  5 in total

1.  Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluación del Control de la Vejiga (CACV).

Authors:  Félix Lugo Salcedo; Rafael Sánchez Borrego
Journal:  Int Urogynecol J       Date:  2013-02-27       Impact factor: 2.894

2.  [Prevalence and characterization of overactive bladder detected in a population in Madrid with self-administered OAB-V3 questionnaire in Primary Care].

Authors:  Javier C Angulo; María P Calderín; Yolanda Fernández; Miriam González; Esther Gómez; Maria B Herreros; Purificación Peñasco; Manuela Zapatero; Juan F Dorado
Journal:  Aten Primaria       Date:  2017-07-24       Impact factor: 1.137

3.  Analysis of the Readability of Questionnaires on Symptoms of Pelvic Floor Dysfunctions Adapted to Spanish.

Authors:  Víctor Checa-Moreno; Esther Díaz-Mohedo; Carmen Suárez-Serrano
Journal:  Int J Environ Res Public Health       Date:  2021-09-30       Impact factor: 3.390

Review 4.  Spanish Questionnaires for the Assessment of Pelvic Floor Dysfunctions in Women: A Systematic Review of the Structural Characteristics and Psychometric Properties.

Authors:  Marina Guallar-Bouloc; Paloma Gómez-Bueno; Manuel Gonzalez-Sanchez; Guadalupe Molina-Torres; Rafael Lomas-Vega; Alejandro Galán-Mercant
Journal:  Int J Environ Res Public Health       Date:  2021-12-06       Impact factor: 3.390

5.  Observational Study on the Prevalence of Urinary Incontinence in Female Athletes.

Authors:  Jorge Velázquez-Saornil; Encarnación Méndez-Sánchez; Sonia Gómez-Sánchez; Zacarías Sánchez-Milá; Ester Cortés-Llorente; Ana Martín-Jiménez; Elena Sánchez-Jiménez; Angélica Campón-Chekroun
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.